Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 1-Year High at $64.58

Alpine Immune Sciences, Inc. (NASDAQ:ALPN)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $64.58 and last traded at $64.58, with a volume of 1793587 shares traded. The stock had previously closed at $64.55.

Analysts Set New Price Targets

Several equities research analysts recently commented on ALPN shares. Wolfe Research reiterated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Royal Bank of Canada restated a “sector perform” rating and set a $65.00 price target (up previously from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Morgan Stanley restated an “equal weight” rating and set a $65.00 price target (up previously from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Guggenheim started coverage on shares of Alpine Immune Sciences in a report on Tuesday, April 9th. They set a “buy” rating and a $55.00 price target for the company. Finally, Wedbush lowered shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Alpine Immune Sciences presently has an average rating of “Hold” and an average target price of $50.33.

Alpine Immune Sciences Price Performance

The firm’s 50 day moving average price is $41.49 and its two-hundred day moving average price is $25.72.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. On average, analysts expect that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Institutional Trading of Alpine Immune Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its stake in Alpine Immune Sciences by 745.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,312 shares in the last quarter. AJOVista LLC bought a new stake in Alpine Immune Sciences during the 4th quarter valued at $64,000. Barclays PLC increased its stake in Alpine Immune Sciences by 44.3% during the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 2,801 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Alpine Immune Sciences by 411.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 4,417 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Alpine Immune Sciences by 75.8% during the 3rd quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 4,155 shares in the last quarter. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.